Pfizer (NYSE:PFE) Trading Down 1.7% – Here’s Why

Pfizer Inc. (NYSE:PFE)’s stock price traded down 1.7% on Monday . The company traded as low as $25.23 and last traded at $25.3050. 53,073,677 shares traded hands during mid-day trading, an increase of 3% from the average session volume of 51,385,086 shares. The stock had previously closed at $25.74.

Wall Street Analyst Weigh In

Several research firms have commented on PFE. Morgan Stanley lowered their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. Finally, Bank of America boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $28.39.

Pfizer Stock Down 1.7%

The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The business has a 50-day moving average of $25.01 and a 200-day moving average of $24.60. The stock has a market capitalization of $143.88 billion, a price-to-earnings ratio of 13.46, a P/E/G ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer’s payout ratio is currently 100.00%.

Institutional Trading of Pfizer

Institutional investors have recently modified their holdings of the stock. Investment Research Partners LLC acquired a new position in shares of Pfizer in the 3rd quarter valued at $332,000. Cambria Investment Management L.P. raised its position in Pfizer by 8.2% during the third quarter. Cambria Investment Management L.P. now owns 397,747 shares of the biopharmaceutical company’s stock worth $10,135,000 after acquiring an additional 30,156 shares during the last quarter. Lantern Wealth Advisors LLC increased its position in Pfizer by 5.4% during the third quarter. Lantern Wealth Advisors LLC now owns 18,126 shares of the biopharmaceutical company’s stock worth $462,000 after buying an additional 925 shares in the last quarter. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Pfizer by 10.4% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 8,547 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 806 shares in the last quarter. Finally, KERR FINANCIAL PLANNING Corp purchased a new stake in Pfizer in the 3rd quarter worth approximately $41,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.